AstraZeneca PLC on 5 July said the US Food and Drug Administration declined to approve its diabetes treatment Farxiga as a supplement to insulin in adults with type 1 diabetes, fanning fresh doubts about use of SGLT2 inhibitors as a treatment for the condition.
In a tersely worded statement, AstraZeneca said it had received a complete response letter from the FDA in reply to...







